Orchid Pharma Ltd

Orchid Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Orchid Pharma Ltd

₹ 1,152 1.14%
01 Jul - close price
orchidpharma.com BSE: 524372 NSE: ORCHPHARMA
About

Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. [1]

Key Points

Product Portfolio
The Co has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardio vascular segment (CVS), nutraceuticals and other oral and sterile products. Its Product portfolio constitute of API - Cephalosporins - Orals, Cephalosporins - Injectables, Veterinary Products & Non-Antibiotics. [1][2]

Website BSE NSE
  • Market Cap ₹ 5,838 Cr.
  • Current Price ₹ 1,152
  • High / Low ₹ 1,360 / 432
  • Stock P/E 61.6
  • Book Value ₹ 240
  • Dividend Yield 0.00 %
  • ROCE 8.93 %
  • ROE 9.72 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company has delivered good profit growth of 22.4% CAGR over last 5 years

Cons

  • Stock is trading at 4.79 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Tax rate seems low
  • Company has a low return on equity of 4.39% over last 3 years.
  • Promoter holding has decreased over last 3 years: -28.2%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
120 96 122 159 180 131 165 160 210 183 199 221 217
118 94 114 143 151 119 147 146 170 161 175 185 188
Operating Profit 2 2 7 16 29 12 18 14 40 22 24 36 29
OPM % 2% 2% 6% 10% 16% 10% 11% 9% 19% 12% 12% 16% 13%
3 3 54 2 -0 3 6 9 40 2 8 7 13
Interest 12 11 10 7 4 8 9 8 7 6 4 4 3
Depreciation 20 20 20 20 27 22 18 8 7 8 8 9 8
Profit before tax -27 -26 32 -9 -2 -14 -3 7 65 11 20 31 30
Tax % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% -11%
-27 -26 32 -9 -2 -14 -3 7 65 11 20 31 33
EPS in Rs -6.67 -6.37 7.84 -2.20 -0.44 -3.45 -0.81 1.65 15.89 2.13 3.99 6.02 6.54
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Sep 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
1,736 1,907 1,736 879 755 644 584 481 451 557 666 819
1,375 1,767 1,416 705 740 622 590 531 413 498 581 709
Operating Profit 362 140 320 174 15 22 -6 -50 38 59 84 111
OPM % 21% 7% 18% 20% 2% 3% -1% -10% 8% 11% 13% 14%
46 81 156 -28 -59 20 42 24 6 57 57 30
Interest 179 520 537 294 347 310 7 6 52 33 33 16
Depreciation 149 244 321 143 146 133 130 118 109 87 55 33
Profit before tax 80 -544 -383 -292 -537 -401 -101 -150 -117 -5 54 92
Tax % -29% 2% 50% 6% 9% 12% 0% 0% 0% 0% 0% -4%
103 -530 -191 -274 -489 -355 -101 -150 -117 -5 54 95
EPS in Rs 14.64 -75.26 -22.41 -30.83 -54.91 -39.94 -11.36 -36.71 -28.70 -1.18 13.28 18.68
Dividend Payout % 20% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: -8%
5 Years: 7%
3 Years: 22%
TTM: 23%
Compounded Profit Growth
10 Years: 8%
5 Years: 22%
3 Years: 41%
TTM: 568%
Stock Price CAGR
10 Years: 30%
5 Years: 186%
3 Years: 12%
1 Year: 130%
Return on Equity
10 Years: %
5 Years: -5%
3 Years: 4%
Last Year: 10%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Sep 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 70 70 85 89 89 89 89 41 41 41 41 51
Reserves 1,076 418 354 82 -432 -763 -844 757 641 637 691 1,168
1,996 3,204 3,211 3,214 3,106 3,202 3,230 566 453 268 331 135
756 1,031 506 577 595 683 518 86 90 148 160 199
Total Liabilities 3,899 4,723 4,156 3,963 3,358 3,211 2,993 1,450 1,224 1,094 1,223 1,552
1,931 2,483 1,697 1,540 1,402 1,291 1,161 858 670 584 573 631
CWIP 350 360 282 280 288 272 278 26 7 10 46 10
Investments 149 124 125 125 125 125 0 0 15 49 50 69
1,468 1,756 2,053 2,017 1,543 1,523 1,553 566 531 452 554 842
Total Assets 3,899 4,723 4,156 3,963 3,358 3,211 2,993 1,450 1,224 1,094 1,223 1,552

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Sep 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
764 175 -370 211 402 6 15 80 24 90 13 131
-309 -998 1,334 -1 -176 -28 45 167 67 113 -27 -316
-478 676 -597 -287 -465 33 -0 -250 -165 -217 31 167
Net Cash Flow -24 -147 367 -76 -239 11 60 -3 -73 -14 18 -18

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Sep 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 19 35 61 156 101 82 88 50 107 105 116 84
Inventory Days 290 190 113 183 196 204 219 257 240 201 217 199
Days Payable 188 214 138 307 410 361 354 110 109 140 130 135
Cash Conversion Cycle 121 12 36 32 -113 -74 -47 197 237 165 204 148
Working Capital Days 38 -99 104 136 -214 -508 -724 197 332 160 179 147
ROCE % 8% -2% 1% 2% -3% -3% -5% -7% -5% -2% 5%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
90.00% 90.00% 90.00% 90.00% 89.96% 89.96% 89.96% 89.96% 72.40% 72.40% 69.84% 69.84%
1.82% 1.79% 1.78% 1.61% 1.48% 1.37% 0.86% 0.81% 8.58% 8.08% 4.14% 1.96%
3.67% 3.35% 3.35% 2.97% 2.97% 2.98% 3.94% 2.62% 13.48% 12.46% 14.51% 17.73%
0.00% 0.04% 0.04% 0.04% 0.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
4.51% 4.83% 4.84% 5.39% 5.55% 5.69% 5.22% 6.60% 5.54% 7.05% 11.52% 10.47%
No. of Shareholders 33,37934,79833,53333,69833,67932,71730,89429,52329,13229,19736,93136,720

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls